

Reva Pharmachem Private Limited

Part - I : Balance Sheet

(All amounts are in Indian Rupees unless otherwise stated)

| Particulars | Note | As at | | |
|--|------|----------------|----------------|------------------|
| | | 31.03.2021 | 31.12.2020 | 31.03.2020 |
| | | Audited | Unaudited | Audited |
| ASSETS | | | | |
| Non Current Assets | | | | |
| a) Financial Assets | | | | |
| i) Investments | 1 | - | 5,000 | 5,000 |
| ii) Others | 2 | - | - | 681,600 |
| | | - | 5,000 | 686,600 |
| Current Assets | | | | |
| a) Financial Assets | | | | |
| iii) Cash and Cash Equivalents | 3 | 236,046 | 352,453 | 527,288 |
| b) Other Current Assets | 4 | - | 463,420 | 431,662 |
| | | 236,046 | 815,873 | 958,950 |
| Total | | 236,046 | 820,873 | 1,645,550 |
| EQUITY AND LIABILITIES | | | | |
| EQUITY | | | | |
| a) Equity Share Capital | 5 | 3,000,000 | 3,000,000 | 3,000,000 |
| b) Other Equity | 6 | (2,838,405) | (2,217,204) | (1,958,291) |
| | | 161,595 | 782,796 | 1,041,709 |
| LIABILITIES | | | | |
| Current Liabilities | | | | |
| a) Financial Liabilities | | | | |
| i) Trade Payables | 7 | | | |
| - total outstanding dues of creditors other than micro enterprises and small enterprises | | - | 15,577 | 90,974 |
| b) Other Current Liabilities | 8 | 7,875 | - | 25,949 |
| c) Provisions | 9 | 66,576 | 22,500 | 101,609 |
| d) Current Tax (Net) | 10 | - | - | 385,308 |
| | | 74,451 | 38,077 | 603,840 |
| Total | | 236,046 | 820,873 | 1,645,550 |

Reva Pharmachem Private Limited
Part - II - Statement of Profit and Loss

(All amounts are in Indian Rupees except share data & per share data unless otherwise stated)

| Particulars | Note | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|---|------|----------------------------------|---|-------------------------------|
| | | Audited | Unaudited | Audited |
| Revenue | | | | |
| Revenue from Operations | 11 | - | - | 25,449,450 |
| Total Revenue from Operations | | - | - | 25,449,450 |
| Other Income | 12 | - | - | 499,576 |
| Total Revenue | | - | - | 25,949,026 |
| Expenses | | | | |
| a) Purchases of stock-in-trade | 13 | - | - | 17,618,574 |
| b) Employee Benefits Expense | 14 | - | - | 838,289 |
| c) Finance Costs | 15 | 61,977 | 61,977 | 1,922,164 |
| d) Other Expenses | 16 | 816,822 | 195,621 | 4,294,719 |
| Total Expenses | | 878,799 | 257,598 | 24,673,746 |
| Profit / (Loss) before exceptional items and tax | | (878,799) | (257,598) | 1,275,280 |
| Exceptional income/(expenses) | 17 | - | - | 22,228,795 |
| Profit / (Loss) before tax | | (878,799) | (257,598) | 23,504,075 |
| Tax Expense | | | | |
| a) Current Taxes | | - | - | 391,257 |
| b) Taxes pertaining to earlier years | | 1,315 | 1,315 | 204,330 |
| c) Deferred Taxes (Net) | | - | - | 6,148,067 |
| Less: MAT Credit Entitlement | | - | - | - |
| d) MAT Credit written off (Refer Note 29) | | - | - | 4,235,891 |
| | | 1,315 | 1,315 | 10,979,545 |
| Profit / (Loss) for the year | | (880,114) | (258,913) | 12,524,530 |
| Other Comprehensive Income | | - | - | - |
| Total Comprehensive Income | | (880,114) | (258,913) | 12,524,530 |
| Earning per equity share for Rs.10/- face value (Continued Operations) | | | | |
| Basic | | (2.93) | (0.86) | 41.75 |
| Diluted | | (2.93) | (0.86) | 41.75 |
| Number of shares used in computing earnings per share (Continued Operations) | | | | |
| Basic | | 300,000 | 300,000 | 300,000 |
| Diluted | | 300,000 | 300,000 | 300,000 |

Reva Pharmachem Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY

| Particulars | Equity Share Capital | Retained Earnings | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|--|-----------------------------|--------------------------|-------------------------|-------------------------|-------------------------|
| Balance at the beginning of the reporting period | 3,000,000 | (1,958,291) | (1,958,291) | (1,958,291) | (14,482,820) |
| Changes during the period | - | - | - | - | - |
| Restated balance at the beginning of the reporting period | 3,000,000 | (1,958,291) | (1,958,291) | (1,958,291) | (14,482,820) |
| Changes during the period | - | - | - | - | - |
| Total Comprehensive Income for the Year | - | (880,114) | (880,114) | (258,913) | 12,524,530 |
| Balance at the end of the reporting period | 3,000,000 | (2,838,405) | (2,838,405) | (2,217,204) | (1,958,291) |

Notes:

1. Retained Earnings: This reserve represents the cumulative profits of the company. This Reserve can be utilised in accordance with the provision of the Companies Act, 2013.

Reva Pharmachem Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

1 Non Current Investments

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|---|------------------|------------------|------------------|
| Investments in Government securities (Unquoted) (At cost) | | | |
| National Savings Certificate (NSC) (Assigned as security to Commercial Taxes Department) | - | 5,000 | 5,000 |
| Total | - | 5,000 | 5,000 |

2 Other Non Current Assets

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|--------------------------|------------------|------------------|------------------|
| Security Deposits | | | |
| Rental Deposits | - | - | 681,600 |
| Total | - | - | 681,600 |

3 Cash and Cash Eequivalents

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|-----------------------------|------------------|------------------|------------------|
| a) Cash on hand | 838 | 838 | 1,938 |
| b) Foreign currency in hand | - | - | 17,687 |
| c) Balance with Banks | 235,208 | 351,615 | 507,663 |
| Total | 236,046 | 352,453 | 527,288 |

4 Other Current Assets

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|-----------------------------|------------------|------------------|------------------|
| a) Prepaid Expenses | - | - | - |
| b) GST - Unutilised ITC | - | 31,758 | - |
| c) IGST - Refund Receivable | - | 431,662 | 431,662 |
| Total | - | 463,420 | 431,662 |

6 Other Equity

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|--------------------------|--------------------|--------------------|--------------------|
| Retained Earnings | | | |
| a) Opening Balance | (1,958,291) | (1,958,291) | (14,482,820) |
| b) Profits for the year | (880,114) | (258,913) | 12,524,530 |
| Total | (2,838,405) | (2,217,204) | (1,958,291) |

Reva Pharmachem Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

7 Trade Payables

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|---|------------------|------------------|------------------|
| a) Total outstanding dues of micro enterprises and small enterprises | - | - | - |
| b) Total outstanding dues of creditors other than micro enterprises and small enterprises | | | |
| - Trade Payables | - | - | - |
| - Trade Payables - Others | - | 15,576 | 90,974 |
| Total | - | 15,576 | 90,974 |

8 Other Current Liabilities

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|----------------------------|------------------|------------------|------------------|
| Others | | | |
| i) Tax Deduction at Source | 7,875 | - | 25,949 |
| Total | 7,875 | - | 25,949 |

9 Provisions

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|------------------------|------------------|------------------|------------------|
| Provision for expenses | 66,575 | 22,500 | 101,609 |
| Total | 66,575 | 22,500 | 101,609 |

10 Current Tax Liabilities

| Particulars | As at 31.03.2021 | As at 31.12.2020 | As at 31.03.2020 |
|------------------|------------------|------------------|------------------|
| Income Tax (Net) | - | - | 385,308 |
| Total | - | - | 385,308 |

11 Revenues

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|----------------|----------------------------------|---|-------------------------------|
| Sales of Drugs | - | - | 25,449,450 |
| Total | - | - | 25,449,450 |

12 Other Income

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|--|----------------------------------|---|-------------------------------|
| a) STCG from Mutual Fund Redemption | - | - | 13,651 |
| b) Fair Value measurement of Investments | - | - | 46,566 |
| c) Interest Income | - | - | 59,465 |
| d) Duty Draw Back Received | - | - | 379,894 |
| Total | - | - | 499,576 |

13 Purchases of stock-in-trade

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|--------------------|----------------------------------|---|-------------------------------|
| Purchases of Drugs | - | - | 17,618,574 |
| Total | - | - | 17,618,574 |

14 Employee Benefits Expense

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|-------------------------|----------------------------------|---|-------------------------------|
| a) Salaries and Wages | - | - | 771,221 |
| b) Bonus and Incentives | - | - | 67,068 |
| Total | - | - | 838,289 |

15 Finance Cost

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|------------------|----------------------------------|---|-------------------------------|
| Interest expense | | | |
| - Others | 61,977 | 61,977 | 1,922,164 |
| Total | 61,977 | 61,977 | 1,922,164 |

Reva Pharmachem Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

16 Other Expenses

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|---|----------------------------------|---|-------------------------------|
| a) Rent | 145,200 | 118,800 | 1,579,200 |
| b) Power Charges | - | - | 86,901 |
| c) Repairs & Maintenance | | | |
| i) Others | - | - | 239,012 |
| d) Rates and taxes | 5,300 | 5,300 | 14,300 |
| e) Insurance Charges | - | - | 19,871 |
| f) Traveling & Conveyance | 4,340 | 4,340 | 6,506 |
| g) Telephone /Mobile/Internet/datacard | 22,766 | 22,766 | 143,404 |
| h) Legal & Professional fees | 91,000 | 30,000 | 412,000 |
| i) Payment to Auditors (Refer Note No.19) | 49,000 | - | 94,000 |
| j) Brokerage & Commission | - | - | 1,687,068 |
| k) Clearing & Forwading Charges | - | - | 222,794 |
| l) Bank charges | 1,850 | 1,201 | 40,592 |
| m) Exchange Loss / (Gain) | 2,992 | 2,992 | (630,059) |
| n) GST Expenses | 489,374 | 10,222 | 234,776 |
| o) Miscellaneous expenses | 5,000 | - | 144,354 |
| Total | 816,822 | 195,621 | 4,294,719 |

17 Exceptional income/(expenses)

| Particulars | For the year ended on 31.03.2021 | For the period 9 months ended on 31.12.2020 | For the year ended 31.03.2020 |
|--|----------------------------------|---|-------------------------------|
| Unsecured loan written back (Refer Note No.30) | - | - | 22,228,795 |
| Total | - | - | 22,228,795 |

Reva Pharmachem Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

5 . Equity Share Capital

| Particulars | As At | As At | As At |
|---|------------------|------------------|------------------|
| | 31.03.2021 | 31.12.2020 | 31.03.2020 |
| Authorised Equity shares 1000000 (P.Y. 1000000), Rs. 10/- each par value | 10,000,000 | 10,000,000 | 10,000,000 |
| Issued subscribed & fully paid up Equity shares 300000 (P.Y. 300000), Rs. 10/- each par value | 3,000,000 | 3,000,000 | 3,000,000 |
| TOTAL | 3,000,000 | 3,000,000 | 3,000,000 |

a) Reconciliation of the number of shares.

| Particulars | 31.03.2021 | 31.12.2020 | 31.03.2020 | 31.03.2021 | 31.12.2020 | 31.03.2020 |
|--|----------------|----------------|----------------|------------------|------------------|------------------|
| | Nos | Nos | Nos | Amount | Amount | Amount |
| Shares outstanding at the beginning of the year | 300,000 | 300,000 | 300,000 | 3,000,000 | 3,000,000 | 3,000,000 |
| Shares Issued during the year | - | - | - | - | - | - |
| Shares outstanding at the end of the year | 300,000 | 300,000 | 300,000 | 3,000,000 | 3,000,000 | 3,000,000 |

b) Right Preferences & Restrictions attached to equity shares:

The company has only one class of equity shares having par value of Rs.10/- per share. Each shareholder is eligible for one vote per share. The dividend proposed by the Board of Directors, if any, is subject to the approval of the shareholder, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the balance assets of the company remaining after distribution of all preferential amounts, in proportion to their shareholding.

c) Shareholders holding more than 5% shares in the Company

| Particulars | 31.03.2021 | 31.12.2020 | 31.03.2020 | 31.03.2021 | 31.12.2020 | 31.03.2020 |
|--------------------------------------|------------|------------|------------|--------------|--------------|--------------|
| | Nos | Nos | Nos | % of Holding | % of Holding | % of Holding |
| Akira Pharma Private Limited | 99999 | 99999 | 99999 | 33.33 | 33.33 | 33.33 |
| JDRG. Infrastructure Private Limited | 100001 | 100001 | 100001 | 33.33 | 33.33 | 33.34 |
| Shilpa Medicare Limited | 100000 | 100000 | 100000 | 33.33 | 33.33 | 33.33 |